Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198171 · ClinicalTrials.gov registry record
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
A clinical trial of Stage I Uterine Corpus Cancer and Stage II Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 243
- Enrollment target
- 1
- Study location
NCT01198171 is a study of Stage I Uterine Corpus Cancer and Stage II Uterine Corpus Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 243 participants, below the 862-participant average among 4 other Stage I Uterine Corpus Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01198171, a study of Stage I Uterine Corpus Cancer and Stage II Uterine Corpus Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 243 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Study of Socioeconomic and Demographic Variables
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2010-01 |
| Est. Completion | 2017-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01198171
The ClinicalTrials.gov registry entry for NCT01198171 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 862-participant average among 4 other Stage I Uterine Corpus Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage I Uterine Corpus Cancer appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01198171 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01198171 about?
NCT01198171 is a clinical study titled "Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer". This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to can...
What is the current status of trial NCT01198171?
This trial is currently completed. The enrollment target is 243 participants. The study started on 2010-01. Estimated completion is 2017-02.
What conditions does trial NCT01198171 study?
This clinical trial studies the following conditions: Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer.
What interventions are being tested in trial NCT01198171?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Study of Socioeconomic and Demographic Variables (OTHER).
Who is sponsoring clinical trial NCT01198171?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01198171 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage I Uterine Corpus Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
RECRUITING · Phase 3
-
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
COMPLETED · Phase 2
-
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
COMPLETED
-
Prognostic Biomarkers in Patients With Endometrial Cancer
COMPLETED
Explore more on PlainTrial
Stage I Uterine Corpus Cancer
All registered trials for this condition
Stage II Uterine Corpus Cancer
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.